Vivoryon Therapeutics N.V. to Present at Upcoming Conferences

Vivoryon Therapeutics N.V. to Present at Upcoming ConferencesHalle (Saale) / Munich, Germany, November 3 , 2025- Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences in November: American Society of...

Halle (Saale), 03/11/2025 (informazione.news - comunicati stampa - salute e benessere)

- Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( ), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences in November:

Date: November 5 – 9, 2025
Location: Houston, TX, USA
Title:
Presentation Time: Thursday, November 6, 10:00 am – 12:00 pm CST / 5:00 pm - 7:00 pm CET
Session: Late-Breaking Research Posters
Abstract number/poster details: TH-PO1206
Attendees: Michael Schaeffer, PhD, CBO; Julia Neugebauer, PhD, COO
Link to conference: American Society of Nephrology | Kidney Week - Annual Meeting (2025)

Date: November 18 – 20, 2025
Location: London, UK
Attendees: Frank Weber, MD, CEO; Julia Neugebauer, PhD, COO
To meet the team contact: IR@vivoryon.com

Date: November 24 – 26, 2025
Location: Frankfurt/M, Germany
Attendee: Julia Neugebauer, PhD, COO
Link to conference: Deutsches Eigenkapitalforum

###

Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com

Investor Contact

Dr. Manuela Bader, Director IR & Communication
Email: IR@vivoryon.com

Sandya von der Weid
Tel: +41 78 680 05 38
Email: svonderweid@lifesciadvisors.com

Media Contact

Valeria Fisher or Verena Schossmann
Tel: +49 175 8041816 / +49 151 219 412 77
Email: vivoryon@trophic.eu

Attachment